论文信息 - Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium - 字舞流文

Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium

D. Campa | F. Canzian | J. Zaucha | P. Gaj | M. Kruszewski | T. Robak | W. Tomczak | J. Walewski | D. Zawirska | K. Warzocha | A. Butrym | G. Mazur | M. Pasiarski | A. Jurczyszyn | S. Kyrcz‐Krzemień | A. Stępień | K. Jamroziak | M. Całbecka | M. Raźny | N. Grzasko | E. Subocz | A. Martino | A. Druzd-Sitek | M. Krawczyk-Kuliś | M. Rymko | M. Wątek | E. Iskierka-Jażdżewska | A. Stein | M. Dudzinski | Malwina Rybicka-Ramos | M. Krawczyk‐Kulis